ClinicalTrials.gg
RecruitingNCT06512207Updated Sep 9, 2025

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

An interventional study of Leuprorelin acetate + Sintilimab and Sintilimab in NSCLC, Stage III and NSCLC, Stage IV, sponsored by Jinzhou Medical University. Recruiting at 1 site in China. Open to male participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Jinzhou Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Dec 2023, registered Jul 2024).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
60 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 21 under way, 4 of them phase 3. sintilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
17th of 45
80 · median 60
Started
2023
with 1 other
No phase
2 of 45
2 open now
Primary completion
2025-12
later than 7 of 20 live
Registered
37th of 45
by date

Among the 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by planned enrollment, is one of 2 that started in 2023, is one of 2 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 37th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 60 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.

Read the detailed description

Immune checkpoint blockades (ICBs) are widely used in the clinical treatment of lung cancer. Studies have shown that the quantity and function of tumor-infiltrating lymphocytes (TILs) are associated with the effectiveness of PD-1 inhibitors in treating advanced NSCLC. The thymus is crucial for the differentiation, development, and maturation of T cells. With age, thymic atrophy leads to immunosenescence, significantly affecting baseline anti-tumor immunity and responses to immunotherapies. Preliminary findings have indicated that androgen deprivation therapy (ADT) not only directly induces apoptosis in prostate cancer cells but also may exert anti-tumor effects by promoting thymic regeneration. Furthermore, anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. Therefore, this study aims to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.

03

Conditions studied

  • NSCLC, Stage III
  • NSCLC, Stage IV

Keywords

  • Androgen Deprivation Therapy (ADT)
  • Leuprorelin acetate
  • NSCLC
  • PD-1 inhibitor
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male patients aged ≥60 years.
  2. performance status score of 0 \~1.
  3. Expected survival time of more than 3 months.
  4. or cytologically diagnosed advanced lung cancer according to the TNM staging system established by AJCC.
  5. Patients who have not previously received any treatment.
  6. Patients with adequate bone marrow function, no significant hepatic, renal, or coagulation dysfunction as per laboratory test criteria.
  7. At least one tumor lesion meeting the following criteria:

    • No prior local treatments such as radiotherapy
    • Not biopsied during the screening period (if needed, baseline tumor assessment at least 14 days after the screening biopsy).
    • Measurable at baseline (longest diameter of the lesion ≥10 mm; For a lymph node, short diameter ≥15 mm).
    • If only one , no prior local treatments such as radiotherapy.
  8. Ability to understand and voluntarily sign a written form.
  9. Willingness to follow the study protocol and follow-up examinations.

Exclusion criteria

Exclusion Criteria:

  • Exclusion of cases that do not meet the inclusion criteria
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Conventional Treatment Group

    40 cases in this group to receive the standard conventional treatment (Chemotherapy + PD-1 Monoclonal Antibody)

    Drug: Sintilimab

  • Experimental
    Conventional Treatment Combined with Leuprolide Group

    40 cases in this group to receive the standard conventional therapy (Chemotherapy + PD-1 Monoclonal Antibody) combined with Leuprorelin acetate, 3.75 mg

    Drug: Leuprorelin acetate + Sintilimab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Complete Response (CR)

    Disappearance of all target lesions, with nodular diseases excluded and target nodules reduced to \<10mm in short axis.

    Time frame: Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment

  2. Number of Participants with Partial Response (PR)

    Reduction of at least 30% in the sum of diameters of all measurable target lesions compared to baseline

    Time frame: Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment

  3. Number of Participants with Disease Progression (PD)

    A 20% increase in the sum of the diameters of all measurable target lesions over the entire study period (using the smallest baseline value if it is the smallest), coupled with an absolute increase in the sum of diameters of at least 5mm. The appearance of one or more new lesions is also considered disease progression.

    Time frame: Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment

  4. Number of Participants with Stable Disease (SD)

    Lesion reduction not meeting PR criteria nor sufficient increase for PD, falling in between these two endpoints. The minimum sum of diameters during the study period can be used as a reference.

    Time frame: Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment

  5. Quantity of Peripheral Blood Lymphocytes

    Assessment of peripheral blood lymphocyte quantity, comparing patients before and after a treatment cycle

    Time frame: Laboratory evaluations are scheduled before treatment, at 3 weeks post-treatment, and at 6 weeks post-treatment

  6. Composition of Peripheral Blood Lymphocytes

    Assessment of peripheral blood lymphocyte composition, comparing patients before and after a treatment cycle

    Time frame: Laboratory evaluations are scheduled before treatment, at 3 weeks post-treatment, and at 6 weeks post-treatment.

  7. Status of Recent Thymic Emigrants (RTEs)

    Assessment of the status of Recent Thymic Emigrants (RTEs), comparing patients before and after a treatment cycle

    Time frame: Evaluations are scheduled before treatment, at 3 weeks post-treatment, and at 6 weeks post-treatment.

07

Study locations

1 of 1 sites recruiting
  • The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Shuangning Yang · Contact(86)15138955506
    • Liping Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — We currently do not plan to share individual patient data (IPD) with other researchers due to confidentiality concerns and ethical restrictions. Additionally, the data collected in this study are considered proprietary and are crucial for ongoing and future research projects.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 24 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2024
First posted
Jul 22, 2024
StartActual
Dec 3, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06512207
Lead sponsor
Jinzhou Medical University
Responsible party
Yu Zhang (Professor, Jinzhou Medical University) — Principal investigator
First posted
Jul 22, 2024
Start date
Dec 3, 2023
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Sep 9, 2025

Study contacts

Wangzhi Wei
Contact
weiwangzhi@jzmu.edu.cn
(86)13941620158
Shuangning Yang
Contact
(86)15138955506
Yu Zhang, Professor
principal investigator · Jinzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leuprolide · Sintilimab

Start the discussion